US Stock MarketDetailed Quotes
VTYX Ventyx Biosciences
- 4.730
- -0.250-5.02%
Close May 17 16:00 ET
- 4.780
- +0.050+1.06%
Post 19:01 ET
333.46MMarket Cap-1459P/E (TTM)
5.130High4.610Low511.07KVolume5.040Open4.980Pre Close2.44MTurnover1.00%Turnover RatioLossP/E (Static)70.50MShares40.58052wk High1.09P/B241.73MFloat Cap1.86552wk Low--Dividend TTM51.11MShs Float47.251Historical High--Div YieldTTM10.44%Amplitude1.865Historical Low4.769Avg Price1Lot Size
Ventyx Biosciences Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -54.02%-47.63M | -68.59%-166.52M | -9.29%-51.66M | -44.50%-34.66M | -233.17%-49.28M | -142.98%-30.92M | -155.55%-98.77M | -221.81%-47.26M | -117.27%-23.99M | -49.37%-14.79M |
| Net income from continuing operations | 0.92%-38.57M | -77.97%-192.96M | -32.77%-46.75M | -77.36%-54.03M | -166.02%-53.25M | -71.26%-38.93M | -29.47%-108.43M | -98.19%-35.21M | -138.47%-30.46M | -28.66%-20.02M |
| Operating gains losses | --98K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 204.48%408K | 100.21%941K | 168.67%403K | 108.66%265K | 34.95%139K | 48.89%134K | 1,466.67%470K | 837.50%150K | 1,311.11%127K | 2,475.00%103K |
| Other non cash items | ---88K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | -512.46%-13.97M | 212.58%5.81M | 39.46%-9.26M | 415.59%13.23M | -240.51%-1.55M | -47.67%3.39M | -228.41%-5.16M | -969.53%-15.3M | 239.74%2.57M | 6.38%1.1M |
| -Change in prepaid assets | -235.05%-5.08M | 107.39%616K | 25.40%-5.06M | 270.23%7.19M | -117.71%-5.27M | -26.30%3.76M | -90.06%-8.34M | -818.40%-6.79M | -121.26%-4.23M | -130.23%-2.42M |
| -Change in payables and accrued expense | -3,092.34%-8.75M | 49.76%5.25M | 48.02%-4.37M | -11.83%6.07M | 6.43%3.83M | -119.07%-274K | -58.28%3.51M | -436.63%-8.41M | 158.24%6.88M | 72.26%3.6M |
| -Change in other current liabilities | -52.58%-148K | 81.90%-59K | 276.77%175K | 59.34%-37K | -38.89%-100K | -51.56%-97K | ---326K | ---99K | ---91K | ---72K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -54.02%-47.63M | -68.59%-166.52M | -9.29%-51.66M | -44.50%-34.66M | -233.17%-49.28M | -142.98%-30.92M | -155.55%-98.77M | -221.81%-47.26M | -117.27%-23.99M | -49.37%-14.79M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 321.04%41.77M | 234.71%100.94M | 132.75%46.13M | -39.39%38.89M | 90.79%34.82M | -14.49%-18.9M | 65.05%-74.93M | 1.57%-140.84M | 187.70%64.16M | 166,009.09%18.25M |
| Net PPE purchase and sale | -191.67%-175K | -86.91%-514K | -88.39%-211K | 50.52%-48K | -596.43%-195K | -57.89%-60K | -4.96%-275K | -133.33%-112K | 52.22%-97K | -154.55%-28K |
| Net investment purchase and sale | 322.67%41.94M | 235.90%101.45M | 132.93%46.34M | -39.40%38.94M | 91.56%35.01M | -14.39%-18.84M | 65.44%-74.66M | 1.62%-140.73M | 188.07%64.26M | --18.28M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 321.04%41.77M | 234.71%100.94M | 132.75%46.13M | -39.39%38.89M | 90.79%34.82M | -14.49%-18.9M | 65.05%-74.93M | 1.57%-140.84M | 187.70%64.16M | 166,009.09%18.25M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 97.72%96.18M | -68.21%53.33M | 105.65%585K | -99.09%1.63M | 893.17%2.47M | 56,465.12%48.65M | -48.15%167.77M | -106.49%-10.36M | 252.91%177.79M | -99.56%249K |
| Net common stock issuance | 98.31%96.09M | -70.73%48.41M | --0 | --0 | ---47K | --48.46M | 4.15%165.4M | -107.01%-11.13M | --176.53M | --0 |
| Proceeds from stock option exercised by employees | -57.41%92K | 107.29%4.92M | -44.14%434K | 34.94%1.7M | 931.33%2.57M | 151.16%216K | 3,552.31%2.37M | 3,600.00%777K | 6,542.11%1.26M | 896.00%249K |
| Net other financing activities | ---- | ---- | ---- | ---78K | ---48K | ---25K | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 97.72%96.18M | -68.21%53.33M | 105.65%585K | -99.09%1.63M | 893.17%2.47M | 56,465.12%48.65M | -48.15%167.77M | -106.49%-10.36M | 252.91%177.79M | -99.56%249K |
| Net cash flow | ||||||||||
| Beginning cash position | -18.92%52.55M | -8.44%64.82M | -78.13%57.59M | 14.06%51.72M | 52.72%63.67M | -8.44%64.82M | 28,912.70%70.79M | 281.63%263.27M | -55.89%45.34M | -25.54%41.69M |
| Current changes in cash | 7,820.00%90.32M | -106.63%-12.25M | 97.51%-4.95M | -97.32%5.85M | -423.44%-11.99M | 95.99%-1.17M | -108.41%-5.93M | -11,094.96%-198.46M | 744.39%217.97M | -92.08%3.71M |
| Effect of exchange rate changes | -125.00%-5K | 71.43%-12K | -1,175.00%-86K | 142.11%16K | 170.37%38K | -52.38%20K | -481.82%-42K | --8K | -265.22%-38K | -285.71%-54K |
| End cash Position | 124.40%142.87M | -18.92%52.55M | -18.92%52.55M | -78.13%57.59M | 14.06%51.72M | 52.72%63.67M | -8.44%64.82M | -8.44%64.82M | 281.63%263.27M | -55.89%45.34M |
| Free cash flow | -54.29%-47.8M | -68.64%-167.04M | -9.48%-51.87M | -44.12%-34.71M | -233.85%-49.48M | -142.72%-30.98M | -154.54%-99.05M | -221.52%-47.38M | -114.21%-24.09M | -49.49%-14.82M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
